Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. Like ORR, FDA considers PFS to be an appropriate surrogate endpoint for accelerated approval, traditional approval, and for measuring direct clinical benefits in certain circumstances.
40 
Let's personalize your content